Skip to main content
Premium Trial:

Request an Annual Quote

NHGRI Informatics Training Programs Could Become Bioinformatics Centers

NEW YORK (GenomeWeb News) — The National Institutes of Health will commit around $1.5 million in the coming fiscal year to fund the development of informatics training programs that could become regional, national, or international centers of excellence in informatics education and bioinformatics centers.

The program, which will fund five or six new grants with up to $230,000 for five years, is a collaboration between the Fogarty International Center, the National Human Genome Research Institute, and the National Library of Medicine.

These grants will be used to establish or continue informatics programs focused on global health and aimed at addressing the particular needs of institutions in low- and middle-income countries.

NIH expects that these institutions will develop sustainable training programs and that they will become centers of excellence that train individuals who use informatics to apply information and communication technologies to global health research.

These research programs also should address specific research-related informatics needs of biomedical and research communities of foreign institutions and raise awareness of and access to informatics resources, which could include short-term training, workshops, or symposia.

Some programs that are more advanced in their informatics studies may use the funds to develop a network of institutions that jointly offer training and research in informatics, and others may help institutions in low- to middle-income countries to develop their own informatics capacities.

More information about the program is available at the NIH’s website.

Filed under

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.